...
首页> 外文期刊>International journal of endocrinology >Impact of the 8 th Edition of the AJCC-TNM Staging System on Estimated Cancer-Specific Survival in Patients Aged 45–54?Years at Diagnosis with Differentiated Thyroid Carcinoma: A Single Center Report
【24h】

Impact of the 8 th Edition of the AJCC-TNM Staging System on Estimated Cancer-Specific Survival in Patients Aged 45–54?Years at Diagnosis with Differentiated Thyroid Carcinoma: A Single Center Report

机译:第8版AJCC-TNM分期系统对45-54岁患者估计癌症特异性生存的影响在诊断甲状腺癌中的诊断:单一中心报告

获取原文
           

摘要

Background . The 8 th edition of the American Joint Committee on Cancer (AJCC) staging system changed the age cutoff for risk stratification of differentiated thyroid carcinoma (DTC), downgrading patients between 45 and 54 years to stage I or II. The aim of our study was to assess cancer-specific survival (CSS) in patients aged 45–54 years, in order to document the prognostic capability of the last edition of the staging system. Methods . We retrospectively reviewed the medical records of 172 patients that from January 1 st , 2005, to May 31 st , 2017, were diagnosed at our institution with DTC when aged 45–54 years. We restaged patients according to the 8 th edition of the staging system and estimated CSS. Results . 101 out of 172 patients (58.7%) were reallocated to a lower stage. Of the 101 downstaged patients, 88 (88.9%) showed a high or intermediate American Thyroid Association (ATA) risk of recurrence. We recorded no cancer-specific deaths. Conclusions . Risk of cancer-specific mortality in patients aged 45–54 years with DTC is low, supporting the prognostic capability of the 8 th edition of the staging system. However, we recommend to consider carefully the significant proportion of patients at intermediate or high risk of recurrence in this group of patients.
机译:背景 。第8版美国癌症联合委员会(AJCC)分期系统改变了分化的甲状腺癌(DTC)的风险分层的年龄截止,降级45至54岁至I II阶段。我们的研究目的是评估45-54岁的患者的癌症特异性生存期(CSS),以便记录上一版本系统的预后能力。方法 。我们回顾性地审查了172名患者的医学记录,2005年1月1日至5月31日至2017年5月31日,在45-54岁的时候在DTC诊断出在我们的机构。根据第8版的分期系统和估计的CSS恢复患者。结果 。 172名患者中的101例(58.7%)重新分配到下阶段。在101名阶下的患者中,88名(88.9%)显示出高或中期的美国甲状腺协会(ATA)的复发风险。我们录得没有癌症特异性死亡。结论。 45-54岁的癌症特异性死亡风险低于DTC,低,支持第8版的分期系统的预后能力。但是,我们建议在这组患者中仔细考虑患者中间体或高风险的大部分患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号